Hormone replacement therapy and breast cancer: estimate of risk: Education debate
Data(s) |
06/08/2005
|
---|---|
Resumo |
The risk of breast cancer arises from a combination of genetic susceptibility and environmental factors. Recent studies show that type and duration of use of hormone replacement therapy affect a women's risk of developing breast cancer.1-7 The women's health initiative trial was stopped early because of excess adverse cardiovascular events and invasive breast cancer with oestrogen and progestogen.6 The publicity increased public awareness of the risks of hormone replacement therapy, and this was heightened by the publication of the million women study.2 However, the recently published oestrogen only arm of the women's health initiative trial suggests that this formulation may reduce the risk of breast cancer.8 To help make sense of the often confusing information,9 women and clinicians need individual rather than population risk data. We have produced estimates that can be used to calculate individual risk for women living up to the age of 79 and suggest the risk |
Identificador |
http://espace.library.uq.edu.au/view/UQ:55646/UQ_PV_55646.pdf |
Idioma(s) |
eng |
Publicador |
BMJ |
Palavras-Chave | #Medicine, General & Internal #Healthy Postmenopausal Women #Randomized Controlled-trial #Estrogen Plus Progestin #Population #320000 Medical and Health Sciences #11 Medical and Health Sciences #1112 Oncology and Carcinogenesis |
Tipo |
Journal Article |